Article Text

Comparison of tulathromycin, azithromycin and azithromycin-rifampin for the treatment of mild pneumonia associated with Rhodococcus equi
  1. M. Venner, DVM, PhD, DECEIM1,
  2. N. Credner, DVM2,
  3. M. Lämmer, DVM3 and
  4. S. Giguère, DVM, PhD, DACVIM4
  1. 1Veterinary Clinic, Trift 4, Destedt 38162, Germany
  2. 2Equine Clinic, School of Veterinary Medicine, Hanover, Germany
  3. 3Veterinary Clinic, Pfingstweide 2, Kaufungen 34260, Germany
  4. 4College of Veterinary Medicine, University of Georgia, Athens, GA, USA
  1. E-mail for correspondence: gigueres{at}


The objectives of the present study were to determine the relative efficacy of tulathromycin, azithromycin, or azithromycin with rifampin for the treatment of pulmonary abscesses on a farm with endemic infections caused by Rhodococcus equi. Foals with ultrasonographic evidence of pulmonary abscesses (abscess score 8.0–15 cm; n=120) were randomly allocated in four equal treatment groups: (1) tulathromycin intramuscularly; (2) azithromycin monotherapy, orally; (3) azithromycin with rifampin, orally; (4) saline intramuscularly as a placebo. Physical examination and thoracic ultrasonography were performed by individuals unaware of treatment group assignment. Foals that worsened were removed from the study. The proportion of foals that recovered without the need for a change in therapy was significantly higher for foals treated with azithromycin (29 of 30) or azithromycin with rifampin (28 of 30) than for foals treated with a placebo (20 of 30). Additionally, azithromycin or azithromycin with rifampin resulted in a significantly faster decrease in the number of abscesses and abscess score compared with a placebo. The proportion of foals treated with tulathromycin that recovered (27 of 30) was not significantly different from that of foals treated with a placebo. Azithromycin alone or in combination with rifampin was beneficial in the study population.

  • Respiratory disease
  • Rhodococcus equi
  • Pneumonia

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.